Avalo Therapeutics Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Avalo Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $46.18. The average 1-year stock price forecast is 233.19% higher than the current stock price, while the lowest is $34 (+145.31%) and the highest is $60 (+332.90%).

Price Target: $46.18 (+233.19%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$34	$46.18	$45	$60
Change	+145.31%	+233.19%	+224.68%	+332.90%

Analyst Ratings

The average analyst rating for Avalo Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	9	9	10	10	11	11
Buy	1	1	1	1	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	10	10	11	11	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alex Thompson CFA Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $36 → $39	Buy	Maintains	$36 → $39	+181.39%	May 15, 2026
Robert Driscoll Wedbush	Wedbush	Buy Reiterates $40 → $34	Buy	Reiterates	$40 → $34	+145.31%	May 14, 2026
Joseph Catanzaro Mizuho Securities	Mizuho Securities	Buy Maintains $39 → $45	Buy	Maintains	$39 → $45	+224.68%	May 14, 2026
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $40 → $35	Buy	Reiterates	$40 → $35	+152.53%	May 14, 2026
Julian Harrison BTIG	BTIG	Buy Maintains $58	Buy	Maintains	$58	+318.47%	May 14, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 59.00K

-100.00%

from 59.00K

Revenue Next Year

n/a

EPS This Year

-2.53

from -5.84

EPS Next Year

-3.11

from -2.53

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	5.40M	18.05M	1.92M	441.00K	59.00K	-
Revenue Growth	-19.42%	234.40%	-89.34%	-77.08%	-86.62%	-100.00%
Gross Profit	-44.72M	-7.94M	-8.02M	-14.84M	-35.29M	-
Gross Margin	-828.47%	-43.98%	-417.05%	-3,363.95%	-59,808.47%	81.60%
Operating Income	-82.13M	-29.94M	-23.44M	-40.87M	-72.93M	-94.03M
Net Income	-84.38M	-41.66M	-31.54M	-35.13M	-78.26M	-86.66M
EPS	-2,331.41	-1,062.65	-113.58	-20.91	-5.84	-2.53
Free Cash Flow	-37.89M	-12.04M	-17.49M	-16.08M	-17.26M	-98.50M
No. Analysts	-	-	-	-	-	12

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	-100.0%
Avg	-100.0%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-1.69
Avg	-2.53
Low	-3.53

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.